Filtering by:
LeukemiaFDA Approves 2 Drugs for Acute Myeloid Leukemia (AML)
The US Food and Drug Administration (FDA) has approved 2 new drugs, Daurismo (glasdegib) and Venclexta (venetoclax), to treat people newly diagnosed with acute myeloid leukemia (AML) who are not candidates for intensive chemotherapy.
Leukemia Survivor Opens Up About His Cancer
Leukemia survivor Lloyd Sutton says the only time he really felt shaky was the night he spent in the emergency room in May 2015.
A Pioneer in Developing Drugs for People with T-Cell Lymphoma
Owen A. O'Connor, MD, PhD, was awarded the prestigious American Cancer Society Clinical Research Professor grant in July 2018. He was selected because of his expertise and ongoing work to develop drugs to improve treatments for people with Hodgkin and non-Hodgkin lymphomas. He's a professor and researcher at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center in New York, New York.
FDA Approves Lumoxiti (Moxetumomab Pasudotox) for Hairy Cell Leukemia
The US Food and Drug Administration (FDA) has approved Lumoxiti (moxetumomab pasudotox-tdfk) for adults with hairy cell leukemia (HCL) that did not get better with at least 2 different previous treatments or got better but then came back.
FDA Approves Tibsovo (Ivosidenib) for Acute Myeloid Leukemia (AML)
The US Food and Drug Administration (FDA) has approved the targeted therapy drug Tibsovo (ivosidenib) to treat some adults with a certain type of acute myeloid leukemia (AML).
Childhood Leukemia Survivor Now a Happy, Active 4th-Grader
Childhood leukemia survivor Maddie Stanton describes herself as a “mainly regular” kid. “I feel good,” she says. Her mother, Denise, says, “We feel lucky every day to be able to have Maddie enjoying life, and being happy, and living.”
FDA Approves Mylotarg (Gemtuzumab Ozogamicin) for Acute Myeloid Leukemia
The US Food and Drug Administration (FDA) has approved Mylotarg (gemtuzumab ozogamicin) for adults and children with certain types of acute myeloid leukemia (AML).
FDA Approves Besponsa (Inotuzumab Ozogamicin) for Acute Lymphoblastic Leukemia in Adults
The US Food and Drug Administration has approved the targeted therapy drug Besponsa (inotuzumab ozogamicin) for adults with B-cell precursor acute lymphoblastic leukemia (ALL) that is not getting better with treatment, or came back after treatment.